Ind-Swift Laboratories is trading at ₹318.14, up 11.75%, after standalone net profit jumped 201.05% year-on-year to ₹24.44 crore in the June quarter.
- EBITDA also rose sharply, supporting the strong results.
- Shareholders approved a ₹137.20 crore preferential warrant issue to promoter-group entities, signaling expansion funding but raising potential dilution concerns.
- Shares extended their sharp August 11 rally.